Idioma:

Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

Barnes, David J ; Dutton, Peter ; Bruland, Øyvind ; Gelderblom, Hans ; Faleti, Ade ; Bühnemann, Claudia ; van Maldegem, Annemiek ; Johnson, Hannah ; Poulton, Lisa ; Love, Sharon ; Tiemeier, Gesa ; van Beelen, Els ; Herbschleb, Karin ; Haddon, Caroline ; Billingham, Lucinda ; Bradley, Kevin ; Ferrari, Stefano ; Palmerini, Emanuela ; Picci, Piero ; Dirksen, Uta ; Strauss, Sandra J ; Hogendoorn, Pancras C W ; Buddingh, Emmeline ; Blay, Jean-Yves ; Cleton-Jansen, Anne Marie ; Hassan, Andrew Bassim

BMC cancer, 2022-06, Vol.22 (1), p.629-629, Article 629 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)
Autor: Barnes, David J ; Dutton, Peter ; Bruland, Øyvind ; Gelderblom, Hans ; Faleti, Ade ; Bühnemann, Claudia ; van Maldegem, Annemiek ; Johnson, Hannah ; Poulton, Lisa ; Love, Sharon ; Tiemeier, Gesa ; van Beelen, Els ; Herbschleb, Karin ; Haddon, Caroline ; Billingham, Lucinda ; Bradley, Kevin ; Ferrari, Stefano ; Palmerini, Emanuela ; Picci, Piero ; Dirksen, Uta ; Strauss, Sandra J ; Hogendoorn, Pancras C W ; Buddingh, Emmeline ; Blay, Jean-Yves ; Cleton-Jansen, Anne Marie ; Hassan, Andrew Bassim
Assuntos: Acetylmuramyl-Alanyl-Isoglutamine - analogs & derivatives ; Antimitotic agents ; Antineoplastic agents ; Bacterial infections ; Bayes Theorem ; Bayesian ; Bayesian analysis ; Biomarkers ; Biopsy ; Bone cancer ; Bone neoplasm ; Bone Neoplasms - pathology ; Chemotherapy ; Cytokines ; Diagnosis ; Drug dosages ; Drug therapy ; Gene expression ; Genomic analysis ; Humans ; Ifosfamide ; Immune system ; Infections ; Liposomes ; Medical research ; Metastases ; Metastasis ; Muramyl tripeptide ; Neoplasm Recurrence, Local - drug therapy ; Osteosarcoma ; Osteosarcoma - pathology ; Patients ; Pattern recognition ; Pharmacodynamics ; Phase II trial ; Phosphatidylethanolamines ; Sarcoma ; Testing ; Toxicity
É parte de: BMC cancer, 2022-06, Vol.22 (1), p.629-629, Article 629
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
Descrição: The phase III clinical study of adjuvant liposomal muramyl tripeptide (MTP-PE) in resected high-grade osteosarcoma (OS) documented positive results that have been translated into regulatory approval, supporting initial promise for innate immune therapies in OS. There remains, however, no new approved treatment such as MTP-PE for either metastatic or recurrent OS. Whilst the addition of different agents, including liposomal MTP-PE, to surgery for metastatic or recurrent high-grade osteosarcoma has tried to improve response rates, a mechanistic hiatus exists in terms of a detailed understanding the therapeutic strategies required in advanced disease. Here we report a Bayesian designed multi-arm, multi-centre, open-label phase II study with randomisation in patients with metastatic and/or recurrent OS, designed to investigate how patients with OS might respond to liposomal MTP-PE, either given alone or in combination with ifosfamide. Despite the trial closing because of poor recruitment within the allocated funding period, with no objective responses in eight patients, we report the design and feasibility outcomes for patients registered into the trial. We demonstrate the feasibility of the Bayesian design, European collaboration, tissue collection with genomic analysis and serum cytokine characterisation. Further mechanistic investigation of liposomal MTP-PE alone and in combination with other agents remains warranted in metastatic OS.
Editor: England: BioMed Central Ltd
Idioma: Inglês;Norueguês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 6 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

England: BioMed Central Ltd

Buscando em bases de dados remotas. Favor aguardar.